Predictive Value of In Vivo MR Spectroscopy With Semilocalization by Adiabatic Selective Refocusing in Differentiating Clear Cell Renal Cell Carcinoma From Other Subtypes
- PMID: 32045306
- DOI: 10.2214/AJR.19.22023
Predictive Value of In Vivo MR Spectroscopy With Semilocalization by Adiabatic Selective Refocusing in Differentiating Clear Cell Renal Cell Carcinoma From Other Subtypes
Abstract
OBJECTIVE. The purpose of this study is to evaluate the diagnostic value of in vivo MR spectroscopy (MRS) with semilocalization by adiabatic selective refocusing (semi-LASER MRS) in differentiating clear cell renal cell carcinoma (RCC) from the non-clear cell subtype. SUBJECTS AND METHODS. Sixteen patients with biopsy-proven RCC or masses highly suspicious for RCC were prospectively recruited to participate in the study. Single-voxel 1H spectra were acquired using a 3-T MRI system, with a semi-LASER sequence acquired for renal tumors in 14 patients and for healthy renal tissue (control tissue) in 12 patients. Offline processing of the MR spectra was performed. MRI and spectra analysis were performed independently by radiologists who were blinded to the reference histopathologic findings. RESULTS. Semi-LASER MRS was diagnostic for nine of 11 patients (82%) with histopathologically proven clear cell RCC, showing a strong lipid peak in seven patients and a weaker lipid resonance in two others, whereas control spectra showed weakly positive findings in only one patient. MRS findings were negative for lipid resonance in two of three patients (67%) with non-clear cell tumors and were weakly positive in another patient. Semi-LASER MRS had a high sensitivity and positive predictive value of 82% and 90%, respectively, in addition to a specificity of 67%, a negative predictive value of 50%, and overall accuracy of 79% for the detection of clear cell RCC. Lipid resonance was detected by MRS for four of six clear cell RCCs with no intravoxel fat on chemical-shift MRI. CONCLUSION. The preliminary results of the present study show that semi-LASER MRS is promising for the noninvasive discrimination of clear cell RCC from non-clear cell RCC on the basis of detection of lipid resonance and that it provides an incremental yield compared with chemical-shift MRI.
Keywords: MR spectroscopy; MRI; renal cell carcinoma; renal tumor; spectroscopy.
Similar articles
-
Predictive Value of Chemical-Shift MRI in Distinguishing Clear Cell Renal Cell Carcinoma From Non-Clear Cell Renal Cell Carcinoma and Minimal-Fat Angiomyolipoma.AJR Am J Roentgenol. 2015 Jul;205(1):W79-86. doi: 10.2214/AJR.14.13245. AJR Am J Roentgenol. 2015. PMID: 26102422
-
Diagnosis of renal tumors by in vivo proton magnetic resonance spectroscopy.World J Urol. 2015 Jan;33(1):17-23. doi: 10.1007/s00345-014-1272-y. Epub 2014 Mar 9. World J Urol. 2015. PMID: 24609220
-
Using the "2 standard deviations" rule with Dixon MRI to differentiate renal cell carcinoma types.Clin Imaging. 2023 Sep;101:113-120. doi: 10.1016/j.clinimag.2023.06.011. Epub 2023 Jun 9. Clin Imaging. 2023. PMID: 37329638
-
Chemical shift magnetic resonance imaging for distinguishing minimal-fat renal angiomyolipoma from renal cell carcinoma: a meta-analysis.Eur Radiol. 2018 May;28(5):1854-1861. doi: 10.1007/s00330-017-5141-0. Epub 2017 Nov 24. Eur Radiol. 2018. PMID: 29178029 Review.
-
Multiparametric MRI of solid renal masses: pearls and pitfalls.Clin Radiol. 2015 Mar;70(3):304-16. doi: 10.1016/j.crad.2014.10.006. Epub 2014 Dec 1. Clin Radiol. 2015. PMID: 25472466 Review.
Cited by
-
Is fat quantification based on proton density fat fraction useful for differentiating renal tumor types?Abdom Radiol (NY). 2025 Mar;50(3):1254-1265. doi: 10.1007/s00261-024-04596-y. Epub 2024 Sep 27. Abdom Radiol (NY). 2025. PMID: 39333411
-
Potential of Metabolic MRI to Address Unmet Clinical Needs in Localised Kidney Cancer.Cancers (Basel). 2025 May 26;17(11):1773. doi: 10.3390/cancers17111773. Cancers (Basel). 2025. PMID: 40507256 Free PMC article. Review.
-
In Vivo Renal Lipid Quantification by Accelerated Magnetic Resonance Spectroscopic Imaging at 3T: Feasibility and Reliability Study.Metabolites. 2022 Apr 23;12(5):386. doi: 10.3390/metabo12050386. Metabolites. 2022. PMID: 35629890 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical